Investor Relations

All the latest information for our investors.

Corporate Overview

RedHill Biopharma (NASDAQ: RDHL) is driven to develop extraordinary medicines for people to live extraordinary lives. RedHill applies innovation, focus and a collective mindset of delivering on our promises, to build a company at the forefront of gastrointestinal and infectious diseases management.

Our three FDA-approved drugs are promoted in the U.S. by a dedicated and experienced sales team, focused on driving increasing revenues.

We have also built an exciting, advanced and largely de-risked R&D pipeline of proprietary late-stage clinical development drug candidates addressing major unmet medical needs.

Our Equity Story

Innovation in gastrointestinal and infectious disease

Commercial excellence driving sustainable revenue growth from three FDA-approved drugs

Exciting, de-risked, late-stage pipeline with multiple near-term catalysts

Clear focus, agility, strength: building a leading specialty company

Events & Presentations

Latest Financial Results

Press Releases

How can we help?